Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs

Neurology
Barbara C TilleyNET-PD Investigators

Abstract

Many agents are being considered for treatment of Parkinson disease (PD). Given the large number of agents and the limited resources to evaluate new agents, it is essential to reduce the likelihood of advancing ineffective agents into large, long-term Phase III trials. Futility design methodology addresses this goal. The authors describe how a single-arm Phase II futility study uses a short-term outcome to compare a treatment group response to a predetermined hypothesized or historically based control response. The authors present advantages and limitations of futility designs along with examples derived from the data archive of a large Phase III efficacy study of treatments to delay PD progression, the Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism (DATATOP) trial. Using the same control progression rate and treatment effect assumptions used to power the original DATATOP trial, the authors calculated the number of subjects needed to conduct two 12-month futility studies. DATATOP was designed to enroll 800 patients. Using data on 124 consecutive subjects randomized into each of the DATATOP treatment groups, the authors identified tocopherol as futile and deprenyl as worthy of further study. Using Phase II informa...Continue Reading

Citations

Jul 2, 2008·Current Neurology and Neuroscience Reports·Tiffini Voss, Bernard Ravina
Jan 24, 2007·Lancet·Francis O Walker
Apr 1, 2009·Journal of Neurotrauma·Susan MarguliesUNKNOWN Combination Therapies for Traumatic Brain Injury Workshop Leaders
Aug 1, 2006·Photomedicine and Laser Surgery
Jun 4, 2008·Clinical Neuropharmacology·UNKNOWN NINDS NET-PD Investigators
Sep 1, 2007·BMJ : British Medical Journal·C E Clarke
Jul 11, 2007·Current Opinion in Neurology·Albert Y Hung, Michael A Schwarzschild
Jan 18, 2012·Current Opinion in Ophthalmology·Harry A Quigley
Feb 15, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·David A Schoenfeld, Merit Cudkowicz
Dec 6, 2011·Lancet Neurology·Karl Kieburtz, Charles Venuto
Sep 24, 2009·Journal of the Neurological Sciences·Matthias Löhle, Heinz Reichmann
Mar 20, 2009·Lancet Neurology·Etienne C Hirsch, Stéphane Hunot
Jul 1, 2015·Contemporary Clinical Trials·Bruce Levin
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Carl E Clarke
Nov 29, 2007·Pharmacotherapy·Mark Lew
Jan 2, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Robert G HartJohn R Marler
Nov 2, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Todd B ShererDeborah W Brooks
Feb 5, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Rodger J ElbleUNKNOWN NINDS NET-PD Investigators
Oct 1, 2006·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jeffrey L Cummings
Jun 28, 2015·Lancet Neurology·UNKNOWN NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
Mar 18, 2015·Nature Reviews. Neurology·Marcus W KochLuanne Metz
Jun 19, 2013·Contemporary Clinical Trials·Charity G MooreDaniel Corcos
Oct 22, 2008·Biochimica Et Biophysica Acta·Talene A Yacoubian, David G Standaert
Jan 26, 2011·Journal of Clinical Neurology·J Eric Ahlskog
Jun 18, 2014·The Cochrane Database of Systematic Reviews·Yousheng XiaoJin Wang
Jul 28, 2013·Stroke; a Journal of Cerebral Circulation·Arthur M PancioliUNKNOWN CLEAR-ER Investigators
Jan 31, 2007·Stroke; a Journal of Cerebral Circulation·Barbara C Tilley, Wendy R Galpern
Sep 4, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Guogen ShanJeffrey L Cummings
Dec 6, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Karl KieburtzC Warren Olanow
Oct 3, 2013·Clinical Trials : Journal of the Society for Clinical Trials·David L Sackett
Jun 27, 2019·Progress in Retinal and Eye Research·Muneeb A FaiqKevin C Chan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.